 Neoplasms, Hormone-Dependent
"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
| Descriptor ID |
D009376
|
| MeSH Number(s) |
C04.626
|
| Concept/Terms |
Neoplasms, Hormone-Dependent- Neoplasms, Hormone-Dependent
- Neoplasms, Hormone Dependent
- Hormone-Dependent Neoplasms
- Hormone Dependent Neoplasms
- Hormone-Dependent Neoplasm
- Neoplasm, Hormone-Dependent
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".
This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in this website by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 0 | 1 | | 1984 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1992 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 2 | 1 | 3 | | 2001 | 2 | 0 | 2 | | 2003 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 3 | 4 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.
-
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
-
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087.
-
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
-
Sighoko D, Fackenthal JD, Hainaut P. Changes in the pattern of breast cancer burden among African American women: evidence based on 29 states and District of Columbia during 1998 to 2010. Ann Epidemiol. 2015 Jan; 25(1):15-25.e10.
-
Greene GL. In memoriam: Elwood Jensen (1920-2012). Endocrinology. 2013 Oct; 154(10):3489-91.
-
Elgazzar S, Zembutsu H, Takahashi A, Kubo M, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Katagiri T, Miki Y, Nakamura Y. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet. 2012 Dec; 57(12):766-71.
-
Nabhan C, Petrylak DP. The role of IMiDs alone or in combination in prostate cancer. Clin Genitourin Cancer. 2012 Sep; 10(3):141-6.
-
Menas P, Merkel D, Hui W, Lawton J, Harper A, Carro G. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract. 2012 Dec; 18(4):387-93.
-
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
-
Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|